Sanofi: Prostatic Neoplasms trials
The registry lists 34 Prostatic Neoplasms studies with Sanofi as lead sponsor. 0 are open to participants now and 14 have results posted.
Phase 1 3Phase 2 16Phase 3 10Phase 4 5No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced MalignanciesTerminatedNCT03367819Phase 1/2Results posted
- Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted AgentCompletedNCT02485691Phase 4Results posted
- Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or EnzalutamideTerminatedNCT02379390Phase 2Results posted
- Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)CompletedNCT01718353Phase 2Results posted
- Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate CancerCompletedNCT01511536Phase 1/2Results posted
- Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate CancerCompletedNCT01308580Phase 3Results posted
- Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT01308567Phase 3Results posted
- Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal TherapyTerminatedNCT00686036Phase 2Results posted
- Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate CancerCompletedNCT00659438Phase 2Results posted
- Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate CancerCompletedNCT00519285Phase 3Results posted
- A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)TerminatedNCT00514917Phase 3Results posted
- E3-Hormone Refractory Prostrate Cancer Taxotere CombinationCompletedNCT00498797Phase 2Results posted
- XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate CancerCompletedNCT00417079Phase 3Results posted
- Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical ProstatectomyCompletedNCT00283062Phase 3Results posted
- Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate CancerCompletedNCT02441894Phase 4
- Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate CancerCompletedNCT02074137Phase 4
- Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate CancerCompletedNCT01649635Phase 4
- Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate CancerCompletedNCT01576029Phase 2
- Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate CancerCompletedNCT01324583Phase 1
- Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing RegimenCompletedNCT01254279Phase 3
- Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) PatientsTerminatedNCT01076751
- Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)CompletedNCT00917748Phase 3
- Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate CancerCompletedNCT00816452
- Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate CancerCompletedNCT00723086Phase 2
- Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate CancerTerminatedNCT00705822Phase 3
- Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate CancerTerminatedNCT00494338Phase 2
- Taxotere Prostate Cancer New Indication Registration Trial in ChinaCompletedNCT00436839Phase 3
- PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With PrednisoloneCompletedNCT00291005Phase 2
- Docetaxel in the Treatment of Hormone Refractory Prostate CancerCompletedNCT00280098Phase 4
- Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]CompletedNCT00268710Phase 2
- Trilostane for Androgen-Independent Prostate CancerCompletedNCT00181597Phase 2
- Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate CancerCompletedNCT00174863Phase 2
- Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With DocetaxelCompletedNCT00082134Phase 2
- A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following ProstatectomyCompletedNCT00069888Phase 2